Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GALR2 | O43603 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CD40 | P25942 | 1/20 | 0.38 |
| ▸ | CD40LG | P29965 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7593462 | 0.96 | KMT2A (0.50) | KMT2ASMN1; SMN2KDM4EHSD17B10NPSR1 | |
| SCHEMBL7593086 | 0.84 | KMT2A (0.48) | KMT2ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL7941828 | 0.80 | TP53 (0.43) | SMN1; SMN2ALDH1A1HPGDMAPTNPC1 | |
| SCHEMBL7598678 | 0.79 | L3MBTL1 (0.52) | KMT2ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL15774437 | 0.79 | HCAR3 (0.49) | KMT2ASMN1; SMN2ALDH1A1LMNAMAPT | |
| SCHEMBL5875056 | 0.78 | KMT2A (0.47) | KMT2ASMN1; SMN2KDM4EHSD17B10NPSR1 | |
| SCHEMBL7590100 | 0.76 | MEN1 (0.45) | KMT2ASMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL15774462 | 0.75 | PTGER4 (0.51) | KMT2AKDM4EMAPTHCAR3L3MBTL1 | |
| SCHEMBL15774415 | 0.75 | HCAR3 (0.55) | KMT2AKDM4EPOLBALDH1A1LMNA | |
| SCHEMBL10487749 | 0.75 | ALDH1A1 (0.39) | SMN1; SMN2KDM4EALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6211177-B1 | SIDE EFFECT REDUCTION | CELL PATHWAYS, INC. | 2001-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | KMT2A 1590/4885SMN1; SMN2 4367/4885KDM4E 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.